Cargando…

Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial

BACKGROUND & AIMS: FALCON 1 was a phase IIb study of pegbelfermin in patients with non-alcoholic steatohepatitis (NASH) and stage 3 fibrosis. This FALCON 1 post hoc analysis aimed to further assess the effect of pegbelfermin on NASH-related biomarkers, correlations between histological assessmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Elizabeth A., Minnich, Anne, Sanyal, Arun J., Loomba, Rohit, Du, Shuyan, Schwarz, John, Ehman, Richard L., Karsdal, Morten, Leeming, Diana J., Cizza, Giovanni, Charles, Edgar D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971179/ https://www.ncbi.nlm.nih.gov/pubmed/36866389 http://dx.doi.org/10.1016/j.jhepr.2022.100661

Ejemplares similares

Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis
por: Luo, Yi, et al.
Publicado: (2021)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

LPA(1) antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis
por: Decato, Benjamin E., et al.
Publicado: (2022)

Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET‐NASH Study
por: Barritt, A. Sidney, et al.
Publicado: (2021)

The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH
por: Loomba, Rohit, et al.
Publicado: (2020)

Molecular Serum Markers of Liver Fibrosis
por: Liu, Tianhui, et al.
Publicado: (2012)

Falconer
por: Cheever, John
Publicado: (1978)

SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH
por: Luo, Yi, et al.
Publicado: (2021)

AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trials
por: Iyer, Janani S., et al.
Publicado: (2023)

Falcon Crest /
por: Mann, Patrick
Publicado: (1985)

The Maltese falcon
por: Hammett, Dashiell, 1894-1961
Publicado: (1944)

Pegbelfermin (BMS‐986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
por: Charles, Edgar D., et al.
Publicado: (2018)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?
por: Genovese, Federica, et al.
Publicado: (2014)

Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model
por: Veidal, Sanne Skovgård, et al.
Publicado: (2012)

The maltese falcon / by Dashiell Hammett.
por: Hammett, Dashiell, 1894-1961
Publicado: (1932)

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH
por: Hydes, Theresa J., et al.
Publicado: (2020)

John Falconer Murison
Publicado: (1910)

Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology
por: Calleja, José L., et al.
Publicado: (2022)

Current therapies and new developments in NASH
por: Dufour, Jean-François, et al.
Publicado: (2022)

Colour atlas of falcon medicine /
Publicado: (2004)

Falconer's The drug, the nurse, the patient
por: Sheridan, Eleanor Sidor
Publicado: (1985)

Dr. Falconer, on the Portland Powder
por: Falconer, William
Publicado: (1801)

A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH
por: Taylor‐Weiner, Amaro, et al.
Publicado: (2021)

Quantification of extracellular matrix remodeling for the non-invasive identification of graft fibrosis after liver transplantation
por: Engel, Bastian, et al.
Publicado: (2023)

Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C Patients
por: Nielsen, Mette J., et al.
Publicado: (2015)

Metabolomic Profiling to Identify Predictors of Response to Vitamin E for Non-Alcoholic Steatohepatitis (NASH)
por: Cheng, Jianfeng, et al.
Publicado: (2012)

Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
por: Cariou, Bertrand, et al.
Publicado: (2021)

FALCON I - Hardware Reference Manual
por: Pacheco, A, et al.
Publicado: (1989)

Sir Walter Scott: the Wounded Falcon
por: Davison, M. H. Armstrong
Publicado: (1970)

Baby falcon rescued on CERN site
por: Bennett, Sophia Elizabeth
Publicado: (2016)

Trapping of Saker Falcon Falco cherrug and Peregrine Falcon Falco peregrinus in Saudi Arabia: Implications for biodiversity conservation
por: Shobrak, Mohammed Y.
Publicado: (2015)

Falcon: A False Ceiling Inspection Robot
por: Muthugala, M. A. Viraj J., et al.
Publicado: (2021)

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
por: Estes, Chris, et al.
Publicado: (2017)

Association of Versican Turnover with All-Cause Mortality in Patients on Haemodialysis
por: Genovese, Federica, et al.
Publicado: (2014)

Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes
por: Fan, Weiguo, et al.
Publicado: (2021)

Serum markers of type III and IV procollagen processing predict recurrence of fibrosis in liver transplanted patients
por: Nielsen, Mette Juul, et al.
Publicado: (2019)

Falcon genomics in the context of conservation, speciation, and human culture
por: Wilcox, Justin J. S., et al.
Publicado: (2019)

Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
por: Traber, Peter G., et al.
Publicado: (2013)

BET Inhibition Improves NASH and Liver Fibrosis
por: Middleton, Sarah A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0qpvuiabtl5u99g51ghrjme4at